Heidelberg Pharma AG provided earnings guidance for the year 2022. The company expects sales revenue and other income of EUR 7.5 million to EUR 9.5 million. Operating loss is expected to be EUR 32.5 million to EUR 36.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.97 EUR | 0.00% | -0.67% | -20.59% |
Apr. 25 | Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 29, 2024 | CI |
Apr. 23 | Transcript : Heidelberg Pharma AG - Special Call |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.59% | 150M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- HPHA Stock
- News Heidelberg Pharma AG
- Heidelberg Pharma AG Provides Earnings Guidance for the Year 2022